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The substantial differences between trypanosomal and leishmanial DNA topoisomerase IB concerning to their homologues in
mammals have provided a new lead in the study of the structural determinants that can be effectively targeted. Leishmania
donovani, the causative agent of visceral leishmaniasis, contains an unusual heterodimeric DNA topoisomerase IB. The
catalytically active enzyme consists of a large subunit (LdTopIL), which contains the non-conserved N-terminal end and the
phylogenetically conserved ‘‘core’’ domain, and of a small subunit (LdTopIS) which harbors the C-terminal region with the
characteristic tyrosine residue in the active site. Heterologous co-expression of LdTopIL and LdTopIS genes in a topoisomerase
I deficient yeast strain, reconstitutes a fully functional enzyme LdTopIL/S which can be used for structural studies. An approach
by combinatorial cloning of deleted genes encoding for truncated versions of both subunits was used in order to find out
structural insights involved in enzyme activity or protein-protein interaction. The role played by the non-conserved N-terminal
extension of LdTopIL in both relaxation activity and CPT sensitivity has been examined co-expressing the full-length LdTopIS
and a fully active LdTopIDS deletion with several deletions of LdTopIL lacking growing sequences of the N-terminal end. The
sequential deletion study shows that the first 26 amino acids placed at the N-terminal end and a variable region comprised
between Ala548 to end of the C-terminal extension of LdTopIL were enzymatically dispensable. Altogether this combinatorial
approach provides important structural insights of the regions involved in relaxation activity and for understanding the
atypical structure of this heterodimeric enzyme.
Citation: Dı ´az Gonza ´lez R, Pe ´rez Pertejo Y, Ordo ´n ˜ez D, Balan ˜a-Fouce R, Reguera RM (2007) Deletion Study of DNA Topoisomerase IB from Leishmania
donovani: Searching for a Minimal Functional Heterodimer. PLoS ONE 2(11): e1177. doi:10.1371/journal.pone.0001177
INTRODUCTION
Leishmania donovani is the etiological agent of visceral leishmaniasis,
a very serious disease transmitted by the bite of female sandflies of
the Phlebotomine and Lutzomyia genera, characterized by fever,
swelling of the spleen and liver and anaemia which may be fatal if
not diagnosed and treated on time [1]. It is well-established the
role played by the host immune system in resistance and healing of
this disease but no effective vaccine has been developed at present.
Current pharmacopoeia against leishmaniasis includes amongst
others; pentavalent antimonium salts, macrolides, aromatic
diamidines and recently alquilphospholipids. Most of them are
plenty of undesirable side effects, or require parental administra-
tion and long-term treatments [2].
DNA topoisomerases are striking candidate targets for leish-
maniasis therapy [3]. These enzymes catalyze changes in the
topological state of duplex DNA during replication, transcription,
recombination and DNA repair processes, by introducing
transient single strain breaks in the nucleic acid backbone.
Trypanosomatid type IB DNA topoisomerases differ from their
homologues in their oligomeric nature. These enzymes are AB
heterodimers with the genes encoding each protomer located on
different chromosomes [4–5]. Genetic analyses identified a gene
for a large subunit, namely LdTopIL,o nL. donovani chromosome
34, encoding for a 636-amino acid polypeptide with an estimated
molecular mass of 73 kDa. This subunit contains a sequence
resembling the core domain of human topoisomerase I (hTopI
from now) and conserves the catalytic ‘‘tetrad’’: Arg-314, Lys-352,
Arg-410 and His-453. LdTopIS, the gene encoding for the small
subunit, is found on L. donovani chromosome 4 and encodes for
a 262-amino acid polypeptide with a predicted molecular mass of
28-kDa. The small subunit includes the ‘‘SKXXY’’ signature
placed at the C-terminal domain of all type I DNA topoisome-
rases, which conserves a tyrosine residue playing role in DNA
cleavage. Gene silencing studies carried out with the Trypanosoma
brucei bi-subunit topoisomerase IB reveals that both subunits are
required for parasite survival [6].
The structural differences between human and kinetoplastid type
IB DNA-topoisomerases make this enzyme an attractive target for
chemotherapeutic intervention [7–9]. Topoisomerase inhibitors fall
into two general categories: compounds that stimulate the formation
of covalent enzyme-DNA complexes or topoisomerase poisons (class
I inhibitors),andproductsthatinterferewiththe enzymaticfunctions
of the enzyme (class II inhibitors). Camptothecin (CPT) is a good
example of a class I topoisomerase poison. This compound has
a strong anti-leishmanial effect in experimental trials [10] and some
analogues are used for the treatment of cancer (see the recent review
by Pommier [11]). CPT is an uncompetitive inhibitor which, by
bindingcovalentlytoDNA,trapstheenzymeinanimmobileternary
complex, preventing the DNA religation step. CPT generates
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kinetoplastic preparations of DNA from trypanosomes, leishmanias
[12] and other protozoan parasites of medical importance [13].
Previous studies have shown that the proteolytic cleavage of
core and catalytic domains in hTopI within the non conserved
linker domain did not affect markedly catalysis. Stewart and co-
workers [14] reconstituted the relaxation activity of human
topoisomerase by adding to the core domain a series of peptides
containing the C-terminal domain, in a proportion of 1:1 in the
presence of DNA. This finding was reinforced by Park and
Sternglanz [15] using a two-hybrid expression system. The authors
identified proteins containing part of the linker and the C-terminal
domain that supplemented the catalytic core of Saccharomyces
cerevisiae topoisomerase I (yTopI).
The objective of this study is to find out structural insights
within the C-extension end of the large subunit needed for
a functional interaction with the small subunit. Our findings reveal
that 75 residues placed at the C-terminal end of LdTopIL and 169
residues placed at the N-terminal extension of LdTopIS are
dispensable for topoisomerization of supercoiled DNA.
MATERIALS AND METHODS
Reagents and culture media
DNA modification and restriction enzymes were provided from
Roche (Basel, Switzerland) and Amersham Biosciences. Pyrococcus
furiosus (Pfu) polymerase was from Stratagene (La Jolla, CA, USA).
Cell culture media, CPT and other chemicals and reagents were
purchased from Sigma (St. Louis, MO). Primers for PCR
amplification were from Sigma Genosys (UK).
Yeast and leishmanial strains
S. cerevisiae strains for protein expression: EKY3 [MAT a ura3-52
his3D200 leu2D1 trp1D63 TopID::TRP1] and MBY3 [MAT
a ura3-52 his3D200 leu2D1 trp1D63, TopID::TRP1 rad52
D::LEU2], both lacking topoisomerase activity, were generously
gifted by Dr. MA Bjornsti (St. Jude Children’s Research Hospital,
Memphis, TN) [16]. Leishmania donovani promastigotes (LEM75,
Ethiopian) were kindly supplied by Dr. J.M. Requena (Centro de
Biologı ´a Molecular ‘‘Severo Ochoa’’, CSIC Madrid, Spain).
Cloning of leishmanial DNA topoisomerase I
Cloning of heterodimeric LdTopIL/S was performed as described
previously [4]. LdTopIL (GenBank #AF303557) gene, was
obtained by the screening of a l-EMBL3 genomic library [17]
whereas gene encoding the small subunit, LdTopIS (GenBank #
AY062908) was amplified using primers based on L. major Friedlin
genome Project and L. donovani genomic DNA as template [18].
C- and N-terminal truncations of LdTopIL/S
The different constructs were obtained by cloning the distinct
PCR fragments in the bis-cistronic vector pESC -URA using
current molecular biology techniques. The restriction sites for
LdTopIL gene were BamH I and Xho I, whereas Not I and Spe I were
chosen for LdTopIS gene. Figure 1 (A and B) shows the lineal
structure of the bi-subunit LdTopIL/S, describing the different
truncations performed on LdTopIL and LdTopIS subunits
(scheme is not at scale).
The sequence of the primers used for gene amplification and
their positions are listed in Table 1. The PCR reaction contained
20 ng of plasmid pSK-LdTopIL or pSK-LdTopIS as template, 250 ng
of each oligonucleotide, 100 mM dNTPs, 5 mlo f1 0 6Pfu buffer
and 2.5 units of Pfu-polymerase for a total volume of 50 ml. The
cycle was composed by a 5 min step at 94uC, followed by 29 cycles
at 94uC for 1 min, 66uC for 1 min and 72uC for 1 min and ending
with 10 min at 72uC. The genes were subcloned into the BamHI/
XhoI sites for the LdTopIL subunit and NotI/SpeI for LdTopIS in the
yeast expression vector pESC -URA under control of promoters
GAL1 and GAL10 respectively.
Yeast expression system
S. cerevisiae strains EKY3 and MBY3 were transformed with the
constructs showed in Figures 1 and 2, using the lithium acetate
method [19]. The promoted GAL expression vectors carrying the
URA3 selection marker were maintained by selection in synthetic
complete S.C. uracil- media. At least four independent clones were
selected from each transformation. Prior to the 6-h induction with
2% galactose, each starter culture was incubated in SC ura- 2%
raffinose medium to eliminate any traces of glucose that might
inhibit the GAL promoter expression. The cells were harvested by
centrifugation, washed and resuspended in TEEG buffer (50 mM
Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 10% glycerol)
supplemented with 0.2 M KCl and protease inhibitors cocktail
[0.1 mg/ml sodium fluoride, 0.8 mg/ml sodium bisulphite,
26Complete MiniH (Roche Molecular Biochemicals)]. Cell
extracts were prepared by disruption with acid-washed glass beads
according to a previously described procedure [20]. Briefly, cells
were subjected to one freeze/thaw cycle at 280uC, lysed by
vortexing with 425–600 mm glass beads and the extracts were
cleared by centrifugation at 150006g for 30 min at 4uC.
Protein purification
The yeast cultures expressing different deletions were harvested,
washed and disrupted as above. The cell extracts were subjected to
double-ammonium sulfate fractionation (35 and 75% saturation)
and the supernatant from the second precipitation was loaded onto
a phosphocellulose (P-11) column. The recombinant proteins (wild-
type and truncations) were eluted at 4uC with a discontinuous
gradient of KCl (0.2, 0.4, 0.6, 0.8 and 1 M) in TEEG buffer,
supplemented with 0.1 mg/ml sodium bisulphite, 0.8 mg/ml NaF
and 0.26 protease inhibitors cocktail. The active fractions were
loaded onto a phenyl-sepharose column and eluted with a discon-
tinuous inverse gradient of KCl (1, 0.8, 0.6, 0.4 and 0.2 M). In order
to reach an appropriate concentration for the different in vitro assays,
the eluate from the phenyl-sepharose column was concentrated by
Microcon YM-30 (MilliporeH). To store it, 40% glycerol was added
to preserve the activity and to keep in a 220uC freezer. Protein was
determined by the Bradford method [21].
DNA relaxation assays
DNA topoisomerase I activity was assayed by the relaxation of
negatively supercoiled plasmid DNA. The reaction mixture in
a total volume of 20-ml contained 0.3 mg of supercoiled Rf I WX
174 DNA, 10 mM Tris-HCl buffer pH 7.5, 5 mM MgCl2,
0.1 mM EDTA, 15 mg/ml bovine serum albumin, 50 mM KCl
and various concentrations of truncated specimens or wild type
proteins. The reaction mixtures were incubated for 30 min at
37uC and stopped adding up to 1% SDS. The enzyme was
digested with the addition of 2 mg of proteinase K, incubating for
1 h. The extent of plasmid DNA relaxation was assessed by
electrophoresis in a 1% agarose gel in 0.1 M Tris borate EDTA
buffer pH 8.0 at 2 V/cm for 14 h. The gels were visualized under
UV illumination after being stained with ethidium bromide
(0.5 mg/ml) and a posterior electrophoresis in the presence of
0.1 mg/ml ethidium bromide, in order to separate the relaxed
topoisomers from the nicked forms [22].
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PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1177RESULTS
Leishmania donovani DNA-topoisomerase IB
(LdTopIL/S)
According to previous reports, LdTopIL/S was cloned, functionally
expressed and purified using a yeast heterologous system [4]. The
linear schematic representation of Fig 1A shows that LdTopIL
contains a non-conserved N-terminal extension (startMet-Glu43),
followed by a region which resembles the hTopI ‘‘core’’ domain
(Arg44-Ser456). Beyond Ser456 the homology with hTopI is lost
dramatically and a non conserved C-terminal extension (Val457-
Val635) displays no apparent function in topoisomerase activity.
This region however, contains a long tail enriched in lysine residues,
which may be putative nuclear localization signals (NLS).
The small leishmanial subunit LdTopIS contains a large non-
conserved N-terminal extension (startMet-Lys211) enriched in
serine residues which precedes to a C-terminal end closely
homologous to the highly conserved C-terminal TopIB domains
in other eukaryotes.
Combinatorial expression of LdTopIL, LdTopIS
deleted genes in a topoisomerase deficient yeast
strain
In order to know the role played by the non-conserved extensions
of both LdTopIL and LdTopIS in topoisomerization of super-
coiled DNA, a gradual deletion approach was carried out. For this
purpose gradually deleted LdTopIL genes were cloned into the
pESC -URA multiple cloning site driven by GAL1 promoter,
remaining the unchanged LdTopIS gene into the multiple cloning
site driven by GAL10 promoter (Fig 1A). The truncated proteins
encoded by these genes lack the 26 first amino acids from the N-
terminal domain (LdTopIDL from now on) and three increasing
length segments from the C-terminal end called LdTopID
467L,
LdTopID
490L and LdTopID
519L. Relaxation of supercoiled DNA
using yeast extracts that express the above-mentioned genes
showed that, with exception of LdTopIDL, which conserved full
enzymatic activity, the other three deletions expressed non active
topoisomerase specimens and thereby the removed peptides were
Figure 1. Heterologous expression of LdTopIL/S and deletions in a topoisomerase-deficient yeast EKY-3 strain. A) Deletions performed on gene
encoding for LdTopIL were LdTopIDL at the N-terminal end, and LdTopID
467L, LdTopI
490L, and LdTopI
519L at the C-terminal end. These four deletions
were cloned together with LdTopIS into the biscistronic pESC -URA for expression in S. cerevisiae. Six micrograms of yeast extracts were assayed in
a plasmid DNA relaxation assay for 30 min at 37uC (as described under ‘‘Experimental Procedures’’). Reaction products were resolved in agarose gel
and subsequently visualized by ethidium bromide staining. The relative position of the negatively supercoiled DNA substrate is indicated by Sc,
whereas the ladder of relaxed DNA topoisomer bands is labeled R. B) Scheme of the LdTopIL and LdTopIS deletions made on the non conserved
extensions of each subunit and the combinations made between them. Deletions were named according to the amino acid position where the
protein was truncated. Distances represented in the drawings are not in scale. C) 10% SDS-PAGE showing the purity of the different truncations used
in the study.
doi:10.1371/journal.pone.0001177.g001
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together in the heterodimer.
A similar approach was carried out deleting peptide segments
from the N-extension end of LdTopIS. In a very recent report, the
authors showed those truncations missing the entire N-terminal
extension (called truncation E210end) or containing a short coil
portion of this region (called truncation E200end) lacked any
identifiable topoisomerase characteristics, in terms of DNA re-
laxation or CPT sensitivity when co-expressed with the large subunit
[23]. A shorter 169 amino acids truncation (LdTopIDSf r o mn o w
on) was then designed. LdTopIDS conserves the a-helix comprised
between amino acids 190 to 208 intact, and an extra sequencewhich
has no identifiable spatial arrangement (amino acids 169 to 189).
This truncated protein relaxed supercoiled DNA at similar extent
that wild type and was inhibited by CPT (data not shown).
Selection of functional topoisomerase truncations
Once regions involved in DNA relaxation were delimited within
each enzymatic subunit, we proceeded to purify active truncated
proteins with no distinguishable topoisomerase activity from wild
type using large scale yeast cultures as described in Materials and
Methods (Fig 1 B, C).
In a first approach we determined the activity of single
truncations at N-terminal end of each subunit. 0.2 mg of each
LdTopIDL/S and LdTopIL/DS truncations and two-fold serially
dilutions were assayed using 0.3 mg of supercoiled close circular
DNA from the virus WX-174 (Rf I) DNA as substrate. No
differences were found between these enzymatic specimens and
wild-type in terms of topoisomerase activity (data not shown).
The combinatory expression of both deleted genes LdTopDL/
DS, served to generate a double truncated protein from EKY3
yeast deficient strain. After induction with galactose and
purification according to the methods previously described,
a relaxation assay was performed under the standard assay
conditions, using similar protein concentrations of the purified
wild type topoisomerase as relaxation control. Fig. 2A shows no
differences in relaxation activities and distributive pattern between
this double truncation and the wild type. For these reasons this
protein specimen was used as minimal structure for further
deletion studies into the large subunit.
We have analyzed the effect of CPT on a yeast-deficient
topoisomerase I strain (MBY-3: TopI D::TRP1 rad52 D::LEU2)
transfected with the bidirectional pESC -URA plasmid bearing the
combination of double deleted LdTopIL and LdTopIS genes. Spot
testsdepictedinFig.2Bshowthatafter2%galactoseinduction,CPT
was as lethal for the cultures transformed with deletions LdTopIDL/
DS as for the wild type. Yeasts transformed with the ‘‘empty’’ vector
(‘‘mock’’) were used as control, showing no response to CPT. These
results agree well with the relaxation assays, showing that
topoisomerase specimens expressed by yeasts were functional in vivo.
Searching for a minimal structure in LdTopIL
Once the double LdTopIDL/DS truncation showed no differences
in relaxation activity with respect to the wild type phenotype,
a further gradual deletion study was carried out in the C-extension
end of LdTopIL. It had been established from the results of Fig. 1
that yeasts transformed with deletions containing up to 52 amino
acids upwards the end of the putative ‘‘core’’ domain, were not able
to relax supercoiled DNA in a standard DNA-relaxation assay. It
seems obvious that the amino acids comprised in this region (Gln-
467 to Glu-519) should be relevant for enzyme integrity and thereby
the truncations performed in this second study might contain them.
The new topoisomerase specimens prepared within the region
comprised betweenAla548 to theprotein end were: LdTopID
548DL,
LdTopID
561DL and LdTopID
575DL, respectively and served to
narrow the region involved, in any extent, in topoisomerization or
protein-protein binding. These constructs were cloned together with
LdTopIDS deletion in the biscistronic pESC -URA vector, expressed
and purified from EKY3 transformed yeast according to the above-
mentioned method.
LdTopID
548DL/DS conserves a 18 amino acids length a-helix
(Glu520 to Val538) which resembles the secondary structure of yeast
topoisomerase I and a putative NLS (Arg476 to Lys491). Figure 3A
shows the activity of the truncation LdTopID
548DL/DSi naD N A
relaxation assay using similar conditionsto those employed in Fig.2.It
is remarkable a weak but clear relaxation activity, as well as a slow
appearing of DNA topoisomers detected in time-course experiments
(Fig. 3B). Spot test experiments show however, no differences between
LdTopID
548DL/DS and wild type in CPT sensitivity (Fig 3C), data
which were reinforced in dose-response experiments (Fig 3D).
Altogether it can be concluded that despite LdTopID
548DL/DSi s
a very weak active protein in relaxing supercoiled DNA, it is a DNA-
cleaving enzyme and thereby susceptible to be poisoned by CPT.
LdTopID
561DL/DS is an intermediary 14 amino acids longer
which displays a putative NLS. Time-course (Fig. 4B) and protein-
dilution assays (Fig. 4A) carried out with purified truncated protein
show slow but detectable topoisomerase activity. Spot test (Fig 4C)
and dose-response (Fig 4D) experiments show no differences in CPT
sensitivity respect wild type, suggesting that DNA-cleaving activity of
this truncation is very likely. Finally LdTopID
575DL/DS (Fig. 5) was
performed in order to assign a role to two lysine-enriched regions
(Lys549 to Leu565 and Lys576 to Glu592) mostly arranged in a-
helix and with putative NLS motifs (according to PSORT-II on-line
software). Protein dilution (Fig. 5A) and time-course (Fig. 5B) assays
show no differences inrelaxation activitybetweenthemand a similar
CPT sensitivity than the wild type (Fig. 5C and 5D), suggesting that
Table 1. Sequences of the primers used in this study to
truncate LdTopIB.
......................................................................
26–635 Forward CGGGATCC ATG GAG GAC CTG AAC TGG TGG
26–635 Reverse CCGCTCGAG CTA CAC CCT CAA AGC TGC
1–468 Forward CGGGATCC ATG AAG GTG GAG AAT AGC
1–468 Reverse CCGCTCGAG TCA CTG CAT CAT CTG CAA CTTG
26–490 Forward CGGGATCC ATG GAG GAC CTG AAC TGG TGG
26–490 Reverse CCGCTCGAG CTA CTT CTT GGC GGT CAC CTC CGC CTT
26–519 Forward CGGGATCC ATG GAG GAC CTG AAC TGG TGG
26–519 Reverse CCGCTCGAG CTA CTC CTC CGT GCC GTA GCT CTC CAG
26–549 Forward CGGGATCC ATG GAG GAC CTG AAC TGG TGG
26–549 Reverse CCGCTCGAG TCA GGC GCC CGA CGT GGA TTTC
26–561 Forward CGGGATCC ATG GAG GAC CTG AAC TGG TGG
26–561 Reverse CCGCTCGAG CTA GGC GGC CCT CTT CTT GCC AG
26–575 Forward CGGGATCC ATG GAG GAC CTG AAC TGG TGG
26–575 Reverse CCGCTCGAG CTA GCT CAA CAC CTT TCC ACC CTT C
169–262 Forward ATAAGAATGCGGCCGC ATG CCC ACG CTG GTG CCT CCG
CGT CCT
169–262 Reverse GACTAGT GGA GAT CAA GTC GCG C
200–262 Forward ATAAGAATGCGGCCGC ATG GAG GAG AAC ATC ATT CGC
ATC
200–262 Reverse GACTAGT GGA GAT CAA GTC GCG C
210–262 Forward ATAAGAATGCGGCCGC ATG AAC AGG CTG TGT CG
210–262 Reverse GACTAGT GGA GAT CAA GTC GCG C
doi:10.1371/journal.pone.0001177.t001
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to drive the enzyme to the nucleus compartment.
DISCUSSION
The existence of an unusual heterodimeric type IB topoisomerase
in trypanosomatids was pointed out by our group in 2003 using
a genomic approach in L. donovani. Since then [4] several reports
have confirmed the presence of multimeric topoisomerases in
other trypanosomatids like Trypanosoma brucei [5] and T. cruzi
(Trypanosoma cruzi Genome Project http://www.tigr.org/tdb/
e2k1/tca1/). This remarkable finding confirmed the results
obtained in a previous report describing a putative topoisomerase
lacking the C-terminal domain in L. donovani [24] and indicated
that the small subunit had been ignored in early studies [25]. Once
resolved the primary amino acidic sequence of both subunits, it is
of a paramount importance to know how these monomers are
assembled to build up a functional heterodimer displaying fully
relaxation activity and susceptible to be inhibited by CPT. It is of
interest therefore, to identify structural insights indispensable for
protein-protein interaction between large and small subunits.
The alignment of the amino acid sequence of LdTopIL/S with
the human counterpart as well as its crystalline configuration show
that overall, structure and catalytic machinery of the human and
leishmanial enzymes are conserved, despite the fact that one of
them is a monomer and the other is a heterodimer [26]. From this
comparison it is very likely that the N-terminal and core domains
are placed at the LdTopIL subunit and the C-terminal end within
the small LdTopIS subunit. However, with the data managed at
present, it is not easy to assign a putative linker domain to
a particular region of the bi-subunit leishmanial enzyme. The
importance of this region is not only due to be a simple connector
between core and C-terminal domains [27], but it contributes to
DNA binding and CPT inhibition, probably by slowing down the
religation step of the nicking-closing reaction [28-29].
The evidences presented here indicate that long extensions placed
at C-terminal end of LdTopIL and at N-terminal end of LdTopIS,
respectively are dispensable in terms of relaxation activity and
sensitivity to CPT. Moreover, the combinatorial association of some
of these truncations restored a fully active enzyme which retained
unaltered the cleavage and religation functions associated to any
topoisomerase, in similar terms of wild-type. Results obtained in the
present work show that at least a 94 amino acids long C-extension
comprised between Gln467 to Ala548, are required to retain
measurable relaxation activity and CPT sensitivity. Despite this
Figure 2. Topoisomerase activity and CPT sensitivity of the double truncation LdTopIDL/DS purified from yeast extracts. A) Protein-dilution
relaxation assay of LdTopIDL/DS truncation (lanes 7 to 12) compared to wild type (lanes 1 to 6). 0.2 Micrograms of purified protein and a two-fold
dilution series were incubated with 0.3 mg of RfI W X174 supercoiled DNA for 30 min at 37uC. B) Spot tests showing the sensibility to CPT of MBY3
yeast strain transformed with the ‘‘empty’’ pESC-URA vector (‘‘mock’’) or carrying the wild type or the double deletion LdTopIDL/DS Exponentially
growing cells in glucose, previously transformed with vectors carrying the corresponding topoisomerase encoding genes, were serially 10-fold
diluted starting from OD595=0.3. Five microliters were spotted on selective media under repressed (2% glucose) or induced (2% galactose)
conditions, in the presence or absence of 15 mM and 30 mM CPT. ‘‘Mock’’ assays were performed under similar assay conditions using the pESC -URA
vector without any insert C) Dose-response curves of these transformed yeast to different concentrations of CPT. A, B and C are pictures
representatives of multiple experiments. D is the average of four independent experiments.
doi:10.1371/journal.pone.0001177.g002
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activity, it conserves a high pI which would permits the ionic
interaction with the small subunit to hold the subunits together [3]
and a putative NLS, as well. Further sequential deletions of the
amino acids placed between truncations LdTopID
561DL/DSa n d
LdTopID
575DL/DS, sited at the C-terminal end of the large subunit,
showed that they were unnecessary for topoisomerization, but they
contained multiple putative NLSs required to drive the assembled
protein to the nucleus. Due to these NLS signals are placed at the C-
terminal extension of the LdTopIL subunit only, it is thereby very
likely that the enzyme assembly takes place in the cytosol before
translocation to the nuclear compartment [3].
With regards to the small subunit, the N-extension domain
comprising the first 169 amino acids seems to be unnecessary for
relaxation and CPT sensitivity. However a further truncation up
to Asn210 led to a neglect of interaction between subunits and
topoisomerase activity. From the results obtained in this paper we
can conclude that this 169 N-terminal extension of LdTopIS is not
required either for the interaction between monomers or re-
laxation and DNA cleavage activities. A recent report shows the
existence of a RPPVVSR motif within the small subunit (amino
acids 175 to 182) required for relaxation activity and CPT
sensitivity, thereby a minimal putative linker should contains these
amino acids to fulfill topoisomerase activity [23].
Strikingly the minimal combined truncation reconstituted LdTo-
pID
548DL/DS fully conserved the sensitivity to CPT. According to
these results it may stated that the sensitivity to this class I inhibitor
resides into amino acids of the core and C-terminal domains as well
as in the RPPVV motif contained into the N-terminal extension of
the small subunit [23]. Marquis and co-workers have shown that the
resistance to CPT displayed by L. donovani LdRCPT.160 strain is
mediated by two amino acid substitutions within the core domain of
the large subunit (Gly185Arg and Asp325Glu) resulting from two
singlenucleotidemutations.In addition,authorsobserveda decrease
in DNA relaxation, presumably due to the presence of these
mutations [30].
Once the dispensable regions are delimited in both subunits, an
essential question arises: what is the role of the long serine-
enriched region placed at LdTopIS? It has been proposed that this
region is suitable to phosphorylation and may participate in the
proteolytic breakdown of the enzyme after CPT exposure [31].
Post-translational down-regulation of the human enzyme occurs
Figure 3. Topoisomerase activity of purified truncation LdTopID
548DL/DS. A) Two-fold serial dilutions of the triple truncation LdTopID
548DL/DS
were assayed in a plasmid DNA relaxation assay for 30 min at 37uC. B) Time-course experiment of topoisomerase activity using 0.2 mg of truncation
LdTopID
548DL/DS per reaction 0.2 Micrograms of purified protein and a two-fold dilution series were incubated with 0.3 mg of RfI W X174 supercoiled
DNA for 30 min at 37uC. Relaxation rate was compared with lane RfII which includes 0.3 mgo fW X174 relaxed DNA C) Spot tests showing the
sensibility to CPT of MBY3 yeast strain transformed with the ‘‘empty’’ pESC-URA vector (‘‘mock’’) or carrying the wild type LdTopIL/S genotype and
deletion LdTopID
548DL/DS D) Dose-response curves of these transformed yeast to different concentrations of CPT. A, B and C are pictures
representatives of multiple experiments. D is the average of four independent experiments.
doi:10.1371/journal.pone.0001177.g003
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independent [32]. Topoisomerase degradation by 26S proteasome
may increase tolerance to DNA cleaving poisons [33] and facilitate
the DNA repairing activity of tyrosyl phosphodiesterase [34].
Altogether this study gives structural insights of the role played by
the C-extension end of the LdTopIL in its protein-to-protein
interaction with the small LdTopIS to build up a fully functional
enzyme. The heterodimeric nature of topoisomerase IB in
trypanosomatids provides for functional complementation using
individual truncated fragments. It is remarkable the lack of function
played by at least 169 amino acids located within the N-terminal
extension of LdTopIS, as well as those placed beyond Ala-548 of the
large LdTopIL. Further truncation from the large subunit results in
a stepwise loss of activity up to Glu-519, truncation deficient in
relaxation activity at all. A very recent finding from another lab
concluded that the amino acids 39–456 of large subunit and 210–
262 of small subunit constitute the minimal interactive portion of the
bi-subunit leishmanial enzyme conserving relaxation activity [35].
However theauthors failindescribinga trueputative linker sincethe
enzymatic activity of this enzymatic specimen is almost undetectable
as well as its sensitivity to CPT.
This paper provides structural insights into the N- and C-
extensions involved in the interaction between protomers to build
up a fully active topoisomerase in Leishmania parasites. These
elements are not only required to reconstitute a putative linker
domain, but also contain unexplored nuclear driving signals and
potential post-translational motifs for down-regulation. Only
a deeper knowledge of the structural design of these non-conserved
regions will help to a full understanding of topoisomerase
mechanisms in these ancient eukaryotes.
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Figure 4. Functional expression of purified LdTopID
561DL/DS truncation. A) Two-fold serial dilutions of truncation LdTopID
561DL/DS were assayed
in a plasmid DNA relaxation assay for 30 min at 37uC. B) Time-course experiment of topoisomerase activity using 0.2 mg of truncation LdTopID
561DL/
DS per reaction C) Spot tests showing the sensibility to CPT of MBY3 yeast strain transformed with the ‘‘empty’’ pESC-URA vector (‘‘mock’’) or carrying
the wild type LdTopIL/S genotype and deletion LdTopID
561DL/DS D) Dose-response curves of these transformed yeast to different concentrations of
CPT. A, B and C are pictures representatives of multiple experiments. D is the average of four independent experiments. Relaxation rate was
compared with lane RfII which includes 0.3 mgo fW X174 relaxed DNA. The ‘‘c’’ lane corresponds to an activity control, using a commercial
topoisomerase.
doi:10.1371/journal.pone.0001177.g004
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